🔎 Trials Near Me

Utama › Kanser Endometrium › Wisconsin

Kajian klinikal Kanser Endometrium di Wisconsin

24 kajian untuk Kanser Endometrium sedang mencari peserta di lokasi di Wisconsin.

Bandar di Wisconsin

Teks kajian rasmi (Bahasa Inggeris)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  • ThedaCare Regional Cancer Center, Appleton
  • ThedaCare Regional Medical Center - Appleton, Appleton
  • Duluth Clinic Ashland, Ashland
  • dan 42 lagi
Mengambil pesertaFasa 2
Semua umur · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05564377

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

  • Medical College of Wisconsin, Milwaukee
Mengambil pesertaFasa 1
Umur 18 ke atas · Wanita · Dikemas kini 2 Okt 2026 · NCT05950464

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • University of Wisconsin Carbone Cancer Center, Madison
Mengambil pesertaFasa 1/2
Umur 12 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT04585750

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

  • Duluth Clinic Ashland, Ashland
  • Saint Vincent Hospital Cancer Center Green Bay, Green Bay
  • Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay
  • dan 8 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Wanita · Dikemas kini 2 Okt 2026 · NCT07198074

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

  • Mayo Clinic Health System - Northwest Wisconsin, Eau Claire
  • Mayo Clinic Health System - Southwest Wisconsin, La Crosse
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Wanita · Dikemas kini 29 Sep 2026 · NCT05051722

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

  • Duluth Clinic Ashland, Ashland
  • Northwest Wisconsin Cancer Center, Ashland
Mengambil pesertaFasa 2
Umur 18 ke atas · Wanita · Dikemas kini 28 Sep 2026 · NCT05112601

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

  • Research Site, Milwaukee
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06218914

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

  • Saint Vincent Hospital Cancer Center Green Bay, Green Bay
  • Medical College of Wisconsin, Milwaukee
Mengambil pesertaFasa 2
Umur 18 ke atas · Wanita · Dikemas kini 24 Sep 2026 · NCT05640999

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

  • Research Site, Madison
Mengambil pesertaFasa 2
Umur 18 hingga 130 · Semua jantina · Dikemas kini 23 Sep 2026 · NCT05489211

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

  • Froedtert & MCW Cancer Center, Milwaukee
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Sep 2026 · NCT07109726

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

  • ThedaCare Regional Cancer Center, Appleton
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Sep 2026 · NCT05059444

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

  • Froedtert and Medical College of Wisconsin, Milwaukee
Mengambil pesertaFasa 2
Umur 18 ke atas · Wanita · Dikemas kini 21 Ogo 2026 · NCT05548296

Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial

  • Froedtert Hospital, Milwaukee
Mengambil peserta
Umur 65 ke atas · Semua jantina · Dikemas kini 20 Ogo 2026 · NCT07227077

FOG-001 in Locally Advanced or Metastatic Solid Tumors

  • University of Wisconsin, Carbone Cancer Center, Madison
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Ogo 2026 · NCT05919264

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

  • University of Wisconsin- Madison, Madison
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Ogo 2026 · NCT05592626

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

  • Research Site, Waukesha
Mengambil pesertaFasa 3
Umur 18 ke atas · Wanita · Dikemas kini 29 Jul 2026 · NCT07044336

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

  • 121, Milwaukee
Mengambil pesertaFasa 2
Umur 18 ke atas · Wanita · Dikemas kini 16 Jul 2026 · NCT06906341

Study of EV for Recurrent Endometrial Carcinoma

  • Froedtert Memorial Lutheran Hospital, Milwaukee
Mengambil pesertaFasa 2
Umur 18 ke atas · Wanita · Dikemas kini 13 Jul 2026 · NCT07139977

Integrated Cancer Repository for Cancer Research

  • Bellin Memorial Hospital, Green Bay
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 19 hingga 110 · Semua jantina · Dikemas kini 29 Jun 2026 · NCT02012699

A Study of Lorigerlimab in Participants With Advanced Solid Tumors

  • Wisconsin Institute Medical Research- UW Cancer Connect, Madison
Mengambil pesertaFasa 2
Umur 18 ke atas · Wanita · Dikemas kini 2 Jun 2026 · NCT06730347

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

  • Froedtert & the Medical College of Wisconsin, Milwaukee
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Nov 2025 · NCT05902988

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Milwaukee
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.